[144] Crinetics Pharmaceuticals, Inc. SEC Filing

Rhea-AI Filing Summary

Form 144 notice for Crinetics Pharmaceuticals, Inc. (CRNX) shows a proposed sale related to an insider option exercise and subsequent planned sale. The filer reports acquisition of 5,000 common shares on 10/01/2025 via exercise of stock options and indicates an intended sale of those 5,000 shares on 10/01/2025 through Morgan Stanley Smith Barney LLC, with an aggregate market value of $208,250.00. The filing lists 94,175,994 shares outstanding. Recent disclosed 10b5-1 sales by the same person, Dana Pizzuti, include sales on 09/02/2025 (5,000 shares, $160,515), 08/22/2025 (30,000 shares, $912,999), and 08/20/2025 (6,492 shares, $189,426.82). The form includes the standard representation that the seller does not possess undisclosed material adverse information and references reliance on a Rule 10b5-1 plan where applicable.

Positive

• Disclosure complies with Rule 144 format including broker, amounts, acquisition method, and prior three-month sales
• Use of a 10b5-1 plan (disclosed for prior sales) indicates pre-arranged trading which can reduce insider timing concerns

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine insider exercise and planned sale under brokered program; recent 10b5-1 sales were disclosed.

The filing documents an option exercise of 5,000 common shares and an immediate planned sale through Morgan Stanley Smith Barney LLC valued at $208,250.00. The amount to be sold represents a de minimis portion of the reported 94,175,994 outstanding shares, and prior 10b5-1 sales by the same person totaled 41,492 shares across August and September 2025. From a market-impact perspective, the disclosed transactions and reliance on a 10b5-1 arrangement are typical insider liquidity events and appear routine given the scale relative to the outstanding share count.

Compliance Officer

TL;DR: Disclosure follows Rule 144 format and affirms 10b5-1 representation; no undisclosed material facts asserted.

The form includes required elements: identity of broker, number of shares, aggregate market value, acquisition method (exercise of stock options), payment method (cash), and prior sales in the three-month window. The filer signs the standard attestation regarding material nonpublic information and notes plan adoption/instruction fields consistent with Rule 10b5-1 reliance. Based solely on the form content, the notice meets procedural disclosure requirements.

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK
Filer CCC
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer

SEC File Number

Address of Issuer

Phone

Name of Person for Whose Account the Securities are To Be Sold

See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.

Relationship to Issuer

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	5000	208250.00	94175994	10/01/2025	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	10/01/2025	Exercise of Stock Options	Issuer			5000	10/01/2025	Cash

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
10b5-1 Sales for DANA PIZZUTI 6055 Lusk Boulevard San Diego CA 92121	Common	09/02/2025	5000	160515.00
10b5-1 Sales for DANA PIZZUTI 6055 Lusk Boulevard San Diego CA 92121	Common	08/22/2025	30000	912999.00
10b5-1 Sales for DANA PIZZUTI 6055 Lusk Boulevard San Diego CA 92121	Common	08/20/2025	6492	189426.82

144: Remarks and Signature

Remarks

Date of Notice

Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1

ATTENTION:

The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.

Signature

ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)

FAQ

What does the Form 144 for CRNX report about the 10/01/2025 transaction?

The form reports acquisition by exercise of stock options of 5,000 common shares on 10/01/2025 and an intended sale of those 5,000 shares through Morgan Stanley Smith Barney LLC with an aggregate market value of $208,250.00.

Who is the seller named in the recent Form 144 activity for CRNX?

The filing identifies prior 10b5-1 sales for Dana Pizzuti and the current notice relates to securities to be sold for that account.

How many shares outstanding does the Form 144 list for Crinetics Pharmaceuticals (CRNX)?

The form lists 94,175,994 shares outstanding.

What prior sales in the past three months are disclosed on this Form 144?

Disclosed 10b5-1 sales by Dana Pizzuti include 09/02/2025 (5,000 shares, $160,515), 08/22/2025 (30,000 shares, $912,999), and 08/20/2025 (6,492 shares, $189,426.82).

Which broker is handling the planned sale disclosed in the Form 144?

The planned sale is to be handled by Morgan Stanley Smith Barney LLC located at 1 New York Plaza, 8th Floor, New York, NY 10004.